DataMEDS AI Reports Q3 2026 Revenue of $2.7M, Net Profit Per Share of $2.72
DataMEDS AI reported Q3 2026 revenue of $2.7 million, representing 50% sequential growth from Q2 2026 but down approximately 11% from Q3 2025 revenue of $3.0 million. The company delivered net profit of $10.5 million and diluted EPS of $2.72, compared to a net loss of $34.3 million and loss per share of $23.07 in Q3 2025, with the turnaround driven by debt extinguishment gains and reduced operating expenses. The company regained full compliance with Nasdaq listing standards on October 19, 2026.
Key takeaways
Q3 2026 revenue of $2.7M up 50% sequentially from Q2 2026 ($1.8M) but down 11% year-over-year from Q3 2025 ($3.0M)
Q3 2026 net profit of $10.5M vs net loss of $34.3M in Q3 2025; EPS of $2.72 diluted vs loss of $23.07 per share year-over-year
Net profit driven by $19.1M gain on debt extinguishment; underlying operating loss was $3.4M
Nine-month 2026 revenue of $6.0M down 72% from $21.7M in nine-month 2025
Company regained full compliance with Nasdaq listing standards on October 19, 2026
Acquired Helomics Corporation cancer diagnostics laboratory in September 2026
Launched Health Lives Here mobile app partnered with NFL Alumni Health platform
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow MEDS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.